Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Darunavir/Cobicistat and Cobicistat on Fostemsavir PK in Healthy Subjects
NCT02277600Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Nov 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Maximum Observed Plasma Concentration at Day 14 and Area Under the Concentration-Time Curve at Day 14. Started Nov 2014; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02277600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277600.